Matthew Frigault, MD, (MGH) is the John and Ashley Ranelli Endowed Scholar in Cancer Innovation and Associate Professor of Medicine at HMS. He is a cellular therapist and bone marrow transplant physician scientist who has extensive preclinical, clinical and translational research experience involving the use of immune effector cell therapy for hematologic and solid tumor malignancies. His work has focused on high-risk patient populations, rare tumor subtypes and immunomodulatory approaches for toxicity mitigation and augmentation of T cell function. He is also the Clinical Director of the Cellular Immunotherapy Program and oversees the clinical research infrastructure for cell and gene therapy.